# A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 Injection

> **NCT06717932** · — · ENROLLING_BY_INVITATION · sponsor: **CorrectSequence Therapeutics Co., Ltd** · enrollment: 8 (estimated)

## Conditions studied

- Beta-Thalassemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06717932
- **Lead sponsor:** CorrectSequence Therapeutics Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-05-15
- **Primary completion:** 2039-11
- **Final completion:** 2039-11
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06717932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06717932, "A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 Injection". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06717932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*